CRISPR Therapeutics (Brazil) Performance
| C2RS34 Stock | 31.52 1.89 6.38% |
CRISPR Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CRISPR Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CRISPR Therapeutics is expected to be smaller as well. CRISPR Therapeutics now shows a risk of 3.01%. Please confirm CRISPR Therapeutics downside deviation, information ratio, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if CRISPR Therapeutics will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
CRISPR |
CRISPR Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,099 in CRISPR Therapeutics AG on October 6, 2024 and sell it today you would earn a total of 53.00 from holding CRISPR Therapeutics AG or generate 1.71% return on investment over 90 days. CRISPR Therapeutics AG is generating 0.0736% of daily returns and assumes 3.006% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than CRISPR, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
CRISPR Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CRISPR Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CRISPR Therapeutics AG, and traders can use it to determine the average amount a CRISPR Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0245
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | C2RS34 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.01 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average CRISPR Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CRISPR Therapeutics by adding it to a well-diversified portfolio.
Things to note about CRISPR Therapeutics performance evaluation
Checking the ongoing alerts about CRISPR Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CRISPR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CRISPR Therapeutics had very high historical volatility over the last 90 days |
- Analyzing CRISPR Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CRISPR Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CRISPR Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CRISPR Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CRISPR Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CRISPR Therapeutics' stock. These opinions can provide insight into CRISPR Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CRISPR Stock analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stocks Directory Find actively traded stocks across global markets |